Erlotinib as Second-Line Therapy for Patients with Advanced Non-Small-Cell Lung Cancer and Wild-Type EGFR Tumors. Journal of Analytical Oncology, [S. l.], v. 4, n. 3, p.  94–101, 2015. DOI: 10.6000/1927-7229.2015.04.03.1. Disponível em: https://neoplasiaresearch.com/index.php/jao/article/view/250. Acesso em: 15 apr. 2026.